Newly spun out company OxStem has raised £16.9m (€21.5m) to develop regenerative meds for the treatment of...
Up To Date
Latest News
Swiss Genentech partner AC Immune has raised CHF42.7m (€38.6m) in order to advance its therapeutic and...
Barcelona-based epigenetics expert Oryzon Genomics has closed a debt funding round of €10.5m, bringing the...
Ipsen is strengthening its ties to long-time development partner Oncodesign, a Dijon-based cancer treatment...
Swiss bank Group UBS has raised US$471m (€412m) for the UBS Oncology Impact Fund, which was set up to invest...
More revenue, more jobs, more financing, more R&D expenditure – all signs point towards sustainable growth in...
Share
